In a lecture at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, Matthew F. Covington, M.D., discussed key findings from recent studies that emphasize the possible prognostic role of positron emission tomography (PET) in de-escalating treatment for breast cancer.
Ultravist Becomes First FDA-Approved Contrast Agent for Contrast-Enhanced Mammography
Ultravist is reportedly the first contrast agent to gain a specific indication for visualization of known or suspected lesions on contrast-enhanced mammography, which was recently recommended by the American College of Radiology as a supplemental imaging alternative to magnetic resonance imaging (MRI) in women with dense breasts at the age of 40 and other risk factors for breast cancer.
Philips Set to Showcase Ultrasound Compact 5500CV at ASE Conference
The new portable ultrasound device, which is being showcased at the American Society of Echocardiography (ASE) conference, offers enhanced cardiac imaging as well as shared transducer interoperability and workflows with existing EPIQ CVx and Affiniti CVx ultrasound systems.
Deep Learning Network Shows Significant Potential for Prostate Cancer Detection on MRI
In multiple datasets from a study involving reviewed data from over 2,700 bi-parametric magnetic resonance imaging (MRI) scans, a deep neural network demonstrated area under the receiver operating characteristic (AUROC) scores ranging from 87 to 89 percent for the detection of clinically significant prostate cancer.
FDA Clears Image Processing Software with Emphasis on Nuclear Medicine Imaging Workflow
The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.
Study Examines Photon-Counting CT for CAD Detection in Patients Having TAVR Procedures
In a study cohort of patients undergoing pre-operative workup for transcatheter aortic valve replacement (TAVR), researchers found the use of photon-counting CT for ultra-high resolution coronary CT angiography had a 96 percent sensitivity rate and an 84 percent specificity rate for the detection of coronary artery disease (CAD).
Deep Learning Detection of Mammography Abnormalities: What a New Study Reveals
In multiple mammography datasets with the original radiologist-detected abnormality removed, deep learning detection of breast cancer had an average area under the curve (AUC) of 87 percent and an accuracy rate of 83 percent, according to research presented at the recent Society for Imaging Informatics in Medicine (SIIM) conference.
Expediting the Management of Incidental Pulmonary Emboli on CT
In a recent video interview from the Society for Imaging Informatics in Medicine (SIIM) conference, Ali Tejani, M.D., discussed pertinent insights on leveraging the value of adjunctive artificial intelligence (AI)-enabled triage software for computed tomography (CT) scans with radiology workflow improvements to achieve “clinically meaningful change” for patients with incidental pulmonary emboli findings.
Study Says AI Mapping More Effective than MRI for Assessing Extent of Prostate Cancer
Combining multimodal imaging data and biopsy data, an artificial intelligence (AI) model provided enhanced sensitivity for defining prostate cancer tumor margins in comparison to conventional magnetic resonance imaging (MRI) assessments.
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
In a recent video interview, Stephen Rose, M.D., reviewed a variety of factors that can impact interpretation of breast imaging for women with breast implants and discussed recent research showing a 22 percent reduction in cancer detection rate for this population in comparison to women without breast implants.
PSMA PET Imaging May Offer Key Prognostic Markers for Prostate Cancer
For patients initially diagnosed with non-metastatic, castration-resistant prostate cancer, pelvic lymph node involvement and five or more polymetastases detected with prostate-specific membrane antigen (PSMA)/ positron emission tomography (PET) are significantly associated with lower overall survival rates, according to recently presented research at the American Society of Clinical Oncology (ASCO) conference.